Mythic Therapeutics Announces Publication of Preclinical Data Highlighting the Differentiating Properties of MYTX-011 in Molecular Cancer Therapeutics
Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, today announced the publication of preclinical data highlighting the differentiating properties of its investigational cMET-targeting ADC, MYTX-011, in Molecular Cancer Therapeutics , a journal of the American Association for Cancer Research (AACR).